Comparison of rhG–CSF primed bone marrow and blood stem cell autografts: an analysis of engraftment in malignant lymphomas and solid tumours
- 1 October 1998
- journal article
- Published by Wiley in European Journal of Haematology
- Vol. 61 (4) , 229-234
- https://doi.org/10.1111/j.1600-0609.1998.tb01707.x
Abstract
Many studies have documented faster engraftment after transplantation with peripheral blood stem cells (PBSC) compared to bone marrow (BM) stem cells. Most comparisons, however, have been between unprimed BM and primed PBSC. We have collected engraftment data on 39 patients from 4 Danish centres and compared G–CSF primed BM with G–CSF primed PBSC in malignant lymphoma and solid tumours. In the lymphoma group 6 BM transplants were compared with 8 PBSC transplants, whereas in the testicular cancer group 16 BM transplants were compared with 9 PBSC transplants. In the lymphoma group, the time to platelet engraftment (platelets >20times109/l unsupported) was median 15 d in PBSC transplants and median 34 d in BM transplants (p=0.003). In the solid tumour patients the difference in time to platelet engraftment was 11 and 18 d in PBSC and BM transplants, respectively (p+ subset analysis of BM and PBSC. This analysis revealed a higher content of lineage restricted cells (CD34+CD61+ and CD34+GlyA+) in PBSC compared to BM. In conclusion, G–CSF mobilized PBSC seems to result in faster engraftment than G–CSF primed BM, which could be explained by an increased number of lineage specific progenitors in PBSC compared to BM.Keywords
This publication has 16 references indexed in Scilit:
- Randomized Trial of Autologous Filgrastim-Primed Bone Marrow Transplantation Versus Filgrastim-Mobilized Peripheral Blood Stem Cell Transplantation in Lymphoma PatientsBlood, 1997
- Nordic Flow Cytometry Standards for CD34+ Cell Enumeration in Blood and Leukapheresis Products: Report from the Second Nordic WorkshopJournal of Hematotherapy, 1996
- Randomised trial of filgrastim-mobilised peripheral blood progenitor cell transplantation versus autologous bone-marrow transplantation in lymphoma patientsThe Lancet, 1996
- Detection of clonal CD34+19+ progenitors in bone marrow of BCL2-IgH- positive follicular lymphoma patientsBlood, 1995
- Autologous progenitor cell transplantation: prior exposure to stem cell- toxic drugs determines yield and engraftment of peripheral blood progenitor cell but not of bone marrow graftsBlood, 1995
- Hematopoietic rescue after high-dose chemotherapy using autologous peripheral-blood progenitor cells or bone marrow: a randomized comparison.Journal of Clinical Oncology, 1995
- A Prospective Randomized Trial Comparing Blood- and Marrow-Derived Stem Cells for Hematopoietic Replacement Following High-Dose ChemotherapyJournal of Hematotherapy, 1995
- Absence of breast cancer cells in a single-day peripheral blood progenitor cell collection after priming with cyclophosphamide and granulocyte-macrophage colony-stimulating factorBlood, 1995
- Effect of peripheral-blood progenitor cells mobilised by filgrastim (G-CSF) on platelet recovery after high-dose chemotherapyThe Lancet, 1992
- GRANULOCYTE-MACROPHAGE COLONY STIMULATING FACTOR EXPANDS THE CIRCULATING HAEMOPOIETIC PROGENITOR CELL COMPARTMENT IN MANThe Lancet, 1988